Followers | 185 |
Posts | 10548 |
Boards Moderated | 0 |
Alias Born | 11/23/2007 |
Tuesday, June 06, 2017 9:35:34 PM
Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time
ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today announced that president and chief executive officer, Tim M. Mayleben, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time.
Me thinks they will find & announce Partners (US and Europe/Asia) or be bought out by Big Pharma in the next 6 months...
Either way, I expect the stock to be north of $60 by EOY.
Recent ESPR News
- Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:19:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 07:09:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:16:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:18:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:13:07 PM
- Esperion to Participate in Upcoming June Investor Conferences • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:14:43 PM
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 07:08:17 PM
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/10/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:31:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:50:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:29:53 AM
- Esperion Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- Esperion to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Esperion to Report First Quarter 2024 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity • GlobeNewswire Inc. • 04/07/2024 06:45:00 PM
- Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 • GlobeNewswire Inc. • 03/25/2024 08:00:00 PM
- U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use • Business Wire • 03/22/2024 10:26:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM